Management tracks: Cyclerion, Alkermes, Alder

A week after completing its spinout from Ironwood, Cyclerion has hired Andreas Busch as chief innovation officer. Busch was EVP, head of R&D and CSO at Shire plc and previously served as EVP, head of drug discovery at Bayer AG (Xetra:BAYN). He joins a management team led by CEO Peter Hecht and President and CSO Mark Currie.

In conjunction with its April 2 launch, Cyclerion Therapeutics Inc. (NASDAQ:CYCN) raised $175 million in a private placement. The company’s pipeline comprises five soluble guanylate cyclase (sGC) programs. Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) retains its gastrointestinal business (see “Splitting Ironwood”)...